A primary challenge in the diagnosis of neurological disorders is differentiating between conditions that share clinical features. Absent of a clear diagnosis, proper
and effective patient care is hindered. Therefore, there is a great need for accessible diagnostic tools that help provide clarity to diagnosing clinicians.
Dr. Todd Levine, Chief Medical Officer and Co-Founder of CND Life Sciences will present as part of a Controversies in Movement Disorders panel discussion at 6:30 pm on May 23, 2022, in Punta Gorda, FL.
In honor of national Parkinson’s month, CN2 news in Rock Hill, SC featured Memory & Movement Charlotte, a medical practice focused on Parkinson’s disease and other neurological conditions, where Medical Director Dr. Sanjay Iyer has recently started offering the Syn-One Test to his patients.
Researchers from La Jolla Institute for Immunology have discovered a genetic signature on the circulating T cells of patients with Parkinson’s disease, which they hope can provide new avenues of research for potential treatments.
Vaxxinity, a “purpose-driven biotechnology company committed to democratizing healthcare across the globe,” announced that it has dosed its first patient with Parkinson’s disease in a Phase 1 study of the vaccine UB-312.
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded two grants to AC Immune, a Swiss-based biopharmaceutical company, to support the development of molecules designed to stop the accumulation of alpha-synuclein and inhibit an inflammatory pathway in Parkinson’s disease.
Boston- and Atlanta-based clinical-stage pharmaceutical company Inhibikase Therapeutics, Inc. published the biochemical rationale for potentially treating Parkinson’s disease with IkT-148009, a highly selective Abelson Tyrosine Kinase (c-Abl) inhibitor.
Boston-based biopharma company Yumanity Therapeutics announced last week that its drug candidate, YTX-7739, met its primary end points in a Phase 1b trial in patients with mild to moderate Parkinson’s disease.
A monoclonal antibody that binds to alpha-synuclein is advancing into a clinical trial after showing positive results in the preclinical phase. The compound, known as ABBV-0805, was developed in collaboration between AbbVie and BioArctic, a Swedish biopharma company that focuses on neurodegenerative diseases.
A hallmark of Parkinson’s disease is the presence of Lewy bodies—abnormal clumps of protein primarily made of alpha-synuclein—the reduction of which is hypothesized to stop or slow the development and progression of Parkinson’s and related diseases such as dementia with Lewy bodies and multiple system atrophy.